. "http://dx.doi.org/10.2174/1871529X11313010003" . "Targeting of NF-kappab signaling pathway, other signaling pathways and epigenetics in therapy of multiple myeloma"@en . . "Targeting of NF-kappab signaling pathway, other signaling pathways and epigenetics in therapy of multiple myeloma" . . "Multiple myeloma (MM) remains an incurable disease, at least for the big majority of patients, in spite of the great progress with new drugs in the last years. New treatment strategies are needed to improve the outcome of patients. At least, five proteasome inhibitors of the next generation with greater efficacy (carfilzomib, marizomib (salinosporamide A, NPI-0052), threonine boronic acid-derived proteasome inhibitor CEP-18770, the peptide-semicarbazone S-2209, the tripeptide mimetic BSc2118, and MLN9708/2238) have been recently tested in preclinical models of MM. Carfilzomib has been recently approved for the treatment of patients with MM who have received at least two prior therapies, including bortezomib and immunomodulatory derivatives (IMiDs, thalidomide, lenalidomide or pomalidomide)."@en . "I, P(NT13836)" . "[E18DDE71BE8F]" . "Targeting of NF-kappab signaling pathway, other signaling pathways and epigenetics in therapy of multiple myeloma" . "109833" . . . . "10.2174/1871529X11313010003" . "RIV/00023736:_____/13:00010697!RIV14-MZ0-00023736" . . "1871-529X" . . . . "18"^^ . . . . "Cardiovascular & hematological disorders drug targets" . . . "NL - Nizozemsko" . "Multiple myeloma (MM) remains an incurable disease, at least for the big majority of patients, in spite of the great progress with new drugs in the last years. New treatment strategies are needed to improve the outcome of patients. At least, five proteasome inhibitors of the next generation with greater efficacy (carfilzomib, marizomib (salinosporamide A, NPI-0052), threonine boronic acid-derived proteasome inhibitor CEP-18770, the peptide-semicarbazone S-2209, the tripeptide mimetic BSc2118, and MLN9708/2238) have been recently tested in preclinical models of MM. Carfilzomib has been recently approved for the treatment of patients with MM who have received at least two prior therapies, including bortezomib and immunomodulatory derivatives (IMiDs, thalidomide, lenalidomide or pomalidomide)." . "RIV/00023736:_____/13:00010697" . "Fuchs, Ota" . "1" . . "apoptosis; IkBalpha; MEK/MAPK; multiple myeloma; NF-kappaB; PI3K/akt/mTOR"@en . "1"^^ . "13" . . . "1"^^ . "Targeting of NF-kappab signaling pathway, other signaling pathways and epigenetics in therapy of multiple myeloma"@en . . .